Advertisement

Topics

Study Showed Lowering LDL-C with Repatha Did Not Impair Cognition

06:20 EDT 18 Aug 2017 | PharmPro

Repatha (evolocumab) Phase 3 cognitive function study results published in The New England Journal of Medicine. The results from one of the largest cognitive function trials support the Repatha safety profile.
Contributed Author: 

Original Article: Study Showed Lowering LDL-C with Repatha Did Not Impair Cognition

NEXT ARTICLE

More From BioPortfolio on "Study Showed Lowering LDL-C with Repatha Did Not Impair Cognition"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...